Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 17, 2003. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific shareholding changes within an employee retirement plan.
Material Changes
The primary material change reported is a decrease in the number of Ordinary Share American Depositary Receipts (ADRs) held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Date of Change: January 16, 2003
- Previous Holdings: 18,281,390 ADRs
- New Holdings: 18,237,538 ADRs
- Average Price: $38.70
Management Commentary and Risks
The filing notes that the Plan is a discretionary fund for current and former employees. Two directors, Dr. J. P. Garnier and Mr. J. D. Coombe, hold an interest in the shares held by the fund in the same capacity as other employees. No specific risks, contingencies, or unusual items regarding the company's operations are disclosed in this text.
Investor Verification Points
- Verify the total number of shares held by the US Retirement Savings Plan as of the reporting date.
- Confirm the specific nature of the "discretionary fund" and its impact on director voting rights or economic exposure.
- Check subsequent filings for any further changes in director interests or plan movements.